

85140_Auto_Edited.docx

Name of Journal: *World Journal of Medical Genetics*

Manuscript NO: 85140

Manuscript Type: OPINION REVIEW

Role of IL-2/IL-2R in pathogenesis of autoimmune disorders: Genetic and therapeutic aspects

Sana Rafaqat, Saira Rafaqat

Abstract

Interleukin-2 (IL-2) is an important cytokine that plays a key role in the immune response. The IL-2 receptor (IL-2R) is composed of three subunits, alpha, beta, and gamma, with the alpha subunit (IL2RA) having the highest affinity for IL-2. Several studies reported that immune dysregulation of IL-2 may cause the tissue injury as well as damage leads to pathogenesis of various autoimmune diseases such as acute necrotizing vasculitis in systemic lupus erythematosus (SLE), inflammatory synovitis in rheumatoid arthritis (RA), salivary and lacrimal gland dysfunction in Sjogren syndrome (SS), obliterative vasculopathy fibrosis in systemic sclerosis (SSc), and inflammatory demyelination in multiple sclerosis (MS). The aim of this review paper was to examine the role of IL-2/IL-2R in various autoimmune disorders, taking into account recent advancements and discoveries, gaps in the current literature, ongoing debates, and potential avenues for future research. The focus of this review is on systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, sjogren syndrome, and multiple sclerosis, which are all linked to the malfunctioning of IL-2/IL-2R. In genetic studies, gene polymorphism of IL-2 such as IL-2 330/T, IL-2 330/G, rs2069763 are involved in increasing the risk of SLE. Furthermore, genetic association of IL-2/IL-2R such as rs791588, rs2281089, rs2104286, rs11594656, rs35285258 are significantly associated with RA susceptibility. The IL-2 polymorphism including rs2069762A, rs6822844T, rs6835457G, rs907715T are significant connection with systemic sclerosis. In addition,

rs2104286 (IL-2), rs11594656 (IL-2RA), rs35285258 (IL-2RB) gene polymorphism are significantly increases the risk of multiple sclerosis. In therapeutic approaches, low-dose IL-2 therapy could regulate Tfr and Tfh cells, resulting in a reduction in disease activity in the SLE patients. In addition, elevated sIL-2R levels in the peripheral blood of SLE patients could be linked to an immunoregulatory imbalance, which may contribute to the onset and progression of SLE. Consequently, sIL-2R could potentially be a target for future SLE therapy. Moreover, Low dose-IL2 was well-tolerated, and low levels of Treg and high levels of IL-21 were associated with positive responses to Ld-IL2 suggested to be a safe and effective treatment for RA. Additionally, low-dose IL-2 treatment improves the exocrine glands' ability to secrete saliva in SS-affected mice. Whereas, Basiliximab targets the alpha chain of the IL-2 receptor suggested as a potential treatment for SSc. Also, pre- and post-treatment with Tregs, MDSCs, and IL-2 may have the potential to prevent EAE induction in patients with MS. It is suggested that further studies should be conducted on IL-2 polymorphism in Sjogren syndrome.

INTRODUCTION

Autoimmune diseases are a significant clinical problem that affects a large number of people worldwide. These diseases arise ¹⁸ when the immune system mistakenly attacks healthy tissues and organs in the body, leading to chronic inflammation, tissue damage, and organ dysfunction. It can affect any part of the body, including the joints, skin, blood vessels, nerves, and endocrine glands. Some common examples of autoimmune diseases include rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, and Sjogren syndrome.

The pathogenesis of autoimmune diseases is complex and multifactorial, involving both genetic and environmental factors. While the exact mechanisms underlying autoimmune diseases are not fully understood, it is believed that they occur due to a failure of the body's immune regulatory mechanisms. This failure allows self-reactive immune cells to escape tolerance mechanisms and attack healthy tissues, leading to the development of autoimmunity ^[1]. Autoimmune diseases progress through three stages:

initiation, propagation, and resolution. The initiation phase involves the activation of self-reactive immune cells and their migration to target tissues. The propagation phase is characterized by the activation and expansion of these self-reactive immune cells, leading to chronic inflammation and tissue damage. The resolution phase is defined by the partial and short-term ability to restore the balance of effector and regulatory responses and the reduction of inflammation [1].

IL-2 is an important cytokine that plays a key role in the immune response. The IL-2 receptor is composed of three subunits, alpha, beta, and gamma, with the alpha subunit (IL2RA) having the highest affinity for IL-2. The IL-2 receptor is expressed on a variety of immune cells, including T cells, B cells, and NK cells [2]. The most abundant type of cell that is influenced by IL-2 is T lymphocytes. IL-2 primarily functions to prompt the production of other cytokines and to increase the growth and proliferation of T lymphocytes that are specific to particular antigens, including CD4+ and CD8+ T lymphocytes. This cytokine also promotes the death of activated T lymphocytes, promotes differentiation into Th1 and Th2 subsets in CD4+ T cells, and plays a critical role in the maturation of CD4+ CD25+ Tregs. Additionally, IL-2 increases the cytotoxic activity of CD8+ cells and stimulates the growth of memory CD8+ cells [3].

Genetic variants in IL2RA and IL2RB may be associated with the development of autoimmune diseases and inflammatory diseases. For example, studies have reported that variants in these genes are associated with the risk of multiple sclerosis. However, there is limited research on the association between genetic variants in IL2RA and IL2RB and the risk of rheumatoid arthritis (RA). Further studies are needed to investigate this potential association and to better understand the role of IL-2 in the pathogenesis of RA [2].

Advancements in genotyping technology and the utilization of single nucleotide polymorphism (SNP) assays have facilitated the application of whole genome association approaches. These approaches involve identifying the correlation between genetic variants and the susceptibility to various autoimmune diseases [2].

Despite advances in diagnosis and treatment, autoimmune diseases remain a significant clinical challenge due to their chronic nature, associated healthcare cost, and impact on young populations during their prime working and reproductive years. Therefore, it is essential to continue to study and understand the mechanisms underlying autoimmune diseases to develop effective treatments and improve the quality of life of affected individuals [1].

The aim of this review paper was to examine the role of IL-2/IL-2R in pathogenesis of various autoimmune disorders, taking into account recent advancements and discoveries, gaps in the current literature, ongoing debates, and potential avenues for future research. The focus of this review is on systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, Sjogren syndrome, and multiple sclerosis, which are all linked to the malfunctioning of IL-2/IL-2R, as depicted in figure 1 and table 1.

The authors utilized various databases, including Google Scholar, PubMed, and Science Direct, to conduct a thorough review of the relevant literature, which was completed on March 30, 2023. The search terms used included pathophysiology, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, Sjogren syndrome, multiple sclerosis, autoimmune disorder, IL-2, and IL-2R. In addition to these search terms, the authors also searched through the references of relevant articles to identify comparable studies. Only clinical investigations published in English were included, and no time restrictions were imposed, although preference was given to more recent studies.




Table 1: Role of IL-2/IL-2R in pathogenesis of autoimmune diseases

Autoimmune diseases

Pathogenesis

Genetics (SNP)

Therapy

Systemic Lupus Erythematosus

Acute necrotizing Vasculitis

IL-2 330/ T (IL-2)

IL-2 330/ G (IL-2)

rs2069763 (IL-2)

rs6822844 G/ T

(IL2-IL21)

Low dose IL-2,

Rituximab

Rheumatoid Arthritis

Inflammatory synovitis

rs791588 (IL2RA)

rs2281089 (IL2RA)

rs2104286 (IL2RA)

Low dose IL-2,

Infliximab

Systemic Sclerosis

Obliterative vasculopathy fibrosis

rs2069762A (IL-2)

rs6822844T (IL2-IL21)

rs6835457G (IL-2)

rs907715T (IL-2)

IL2-384-G (IL-2)

rs11594656 (IL-2RA)

rs2104286(IL-2)

rs12722495 (IL-2)

Low dose IL-2,

Basiliximab

Multiple Sclerosis

Inflammatory demyelination

rs2104286 (IL-2)

rs11594656 (IL-2RA)

rs35285258 (IL-2RB)

Tregs,

MDSCs,

IL-2

Sjogren Syndrome

salivary and lacrimal glands dysfunction

No data

Low dose IL-2

24

Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects the entire body, causes persistent and severe pain, and is characterized by the production of autoantibodies and inflammation in multiple organs. SLE is a complex and multifactorial disease that has an unpredictable relapsing-remitting course, resulting from various interactions between susceptibility genes, epigenetics, environmental factors, hormones, and immuno-regulatory variables. The disease can manifest with a broad range of clinical symptoms [4]. In SLE, autoantibodies that are directed against nucleic acids and their binding proteins are produced, indicating a general lack of self-tolerance. Recent research has identified over 30 genetic loci that are associated with the pathogenesis of the disease. The loss of tolerance and subsequent immunological dysregulation in SLE is caused by genetic factors in conjunction with environmental triggers and stochastic events [5].

The IL-2 gene has been linked to autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. The genetic association of rs2069763 in IL-2 was investigated in the Han Chinese SLE patients and a healthy control group in Taiwan. The findings suggest that the G allele of the mutation is significantly more prevalent in SLE patients and may be linked to the genetic origin of SLE in Taiwanese individuals. The study also found that the G allele is significantly higher in SLE patients with antinuclear antibodies and significantly lower in those with discoid rash [6]. Another study investigated the

impact of the IL2/IL21 region, a genetic locus associated with global autoimmunity, on the response to rituximab in individuals with SLE and other autoimmune disorders. The study found that the rs6822844 G/T polymorphism at the IL2-IL21 region was significantly associated with response to rituximab in SLE patients, but not in individuals with other autoimmune disorders. The study suggests that the IL2-IL21 region may influence the response to rituximab in SLE patients specifically [7]. Furthermore, variations in the KIAA1109-interleukin 2 (IL2)-IL21 block on chromosome 4q27 have been associated with various autoimmune disorders. The research findings confirm the link between autoimmune disorders and the KIAA1109/IL2/IL21 gene region, indicating that the 4q27 Locus may contribute to the genetic predisposition of autoimmune disorders in the Tunisian population [8]. A study investigated the association between certain SNPs in the IL-2 and IFN- γ genes and the development of juvenile systemic lupus erythematosus (JSLE), a severe autoimmune disease with an unknown cause. The study found a negative allelic association for JSLE in IL-2 330/T and a positive allelic association for IL-2 330/G. The study suggests that IL-2 cytokine gene polymorphisms could serve as genetic risk indicators for JSLE [9].

Studies have investigated the cytokine profiles of SLE patients and found that peripheral blood mononuclear cells (PBMCs) from SLE patients grow less than controls when activated with antigens and mitogens. Lupus T cells release less IL-2 compared to normal T cells and are less sensitive to IL-2 activation. However, the expression of IL-2 is higher in freshly produced SLE PBMCs compared to normal PBMCs. When stimulated optimally, lupus T cells are capable of producing normal levels of IL-2. The reduced *in vitro* IL-2 production from lupus T cells is likely due to several mechanisms, including the downregulating effects of Th2 cytokines [10]. SLE patients have notably increased levels of sIL-2R in their serum, which are strongly associated with disease activity. Additionally, research study has revealed for the first time that sIL-2R present in the peripheral blood of SLE patients can combine with IL-2 to form a complex that reduces IL-2's biological effectiveness and detection level. This complex also hinders the development of Treg cells and disrupts peripheral tolerance. The research finding

³ suggests that elevated sIL-2R levels in the peripheral blood of SLE patients could be linked to an immunoregulatory imbalance, which may contribute to the onset and progression of SLE. Consequently, sIL-2R could potentially be a target for future SLE therapy ^[11].

SLE is characterized by an imbalance between effector and regulatory CD4⁺ T cells. T cell subsets are regulated by IL-2, and SLE patients have lower levels of IL-2. In this study, researchers found that low doses of recombinant human IL-2 therapy reduced disease activity in SLE patients by selectively affecting the number ¹ of regulatory T (Treg), follicular helper T (TFH), and IL-17-producing helper T (TH17) cells, but not Th1 or Th2 cells ^[12]. In a clinical trial, researchers investigated the effect of low-dose IL-2 on T follicular regulatory (Tfr) and T follicular (Tfh) cells in patients with SLE. They found that low-dose IL-2 therapy could regulate Tfr and Tfh cells, resulting in a reduction in disease activity ^[13]. In addition, open-label clinical trials have suggested that low-dose IL-2 may be a useful treatment for SLE, but a double-blind, placebo-controlled study is necessary to properly evaluate its safety and effectiveness. Overall, low-dose IL-2 therapy may be beneficial and well-tolerated in the treatment of SLE ^[14].

The inadequate production of IL-2 is one of the factors that contributes to the disruption of the immune system leading to SLE. Multiple SLE models in mice have revealed a shortage of IL-2, providing valuable insights into the link between SLE and IL-2. Furthermore, research has shown that ³ IL-15 and IL-21, which are members of the IL-2 family, are also dysregulated in SLE. Imbalanced transcriptional regulators in T cells of SLE patients lead to reduced IL-2 Levels as they are responsible for the synthesis or suppression of IL-2 production ^[15]. It has been recently found that the lymphoproliferation observed in IL-2/IL-2R deficient mice is associated with a significant decrease in the number of Treg in the periphery. Similarly, individuals with SLE have a lower count of regulatory T cells. Although SLE patients do not exhibit significant lymphoproliferation as observed in knockout mice, they do have lower IL-2 Levels. Nonetheless, knockout mice with IL-2/IL-2R deficiency have additional features

that are present in SLE patients, such as production of autoantibodies, lymphadenopathy, and decreased Treg cells [15].

Rheumatoid Arthritis (RA)

Rheumatoid Arthritis (RA) is a medical condition characterized by long-term inflammation of the joints that eventually leads to the deterioration of bone and cartilage, causing systemic inflammation, abnormal antibody production, and persistent synovitis leads to severe disability and early death [4]. The development of RA is an imbalance in the subsets of CD4 + T lymphocytes, including T helper (Th) 17 cells, regulatory T (Treg) cells, T follicular helper (Tfh) cells, and T follicular regulatory (Tfr) cells. These cells contribute to autoimmune inflammatory responses by promoting the excessive production of cytokines and abnormal autoantibodies including anti-cyclic citrullinated peptide and rheumatoid factor [16].

The use of SNP assays and advances in genotyping technology has facilitated the application of whole genome association approaches to link genetic variants with disease susceptibility. Heritability studies have shown that genetic susceptibility plays a critical role in the progression of joint destruction in RA, estimated at 45% to 58%. Various SNPs have been identified to be associated with RA predisposition. In addition, large-scale genome-wide association studies have identified over 30 Loci that play a role in RA pathogenesis. Several genetic factors, including human leukocyte antigen gene (*HLA*), interleukin genes (*IL23R*, *IL6*, *IL17*, and *IL12B*), autoimmune regulator gene (*AIRE*), protein tyrosine phosphatase 22 (*PTPN22*) gene, and solute carrier family 22 member 4 (*SLC22A4*), have been implicated in the pathogenesis of RA.

The cytokine IL-2, which is produced by Th1 Lymphocytes, may play a significant role in the development of RA. The research examined changes in the levels of IL-2 in the bloodstream and determined if there was a relationship between these changes and glucose metabolism abnormalities, including insulin resistance in RA patients. The study revealed that individuals with RA exhibit changes in IL-2 regulation, and that there is a substantial association between IL-2 Levels in the bloodstream and insulin sensitivity [17]. In another study, the connection between serum levels of IL-2 and

disease activity, absolute numbers of peripheral lymphocyte subsets, autoantibodies, and cytokines in individuals with RA patients were examined. The findings demonstrated that serum levels of IL-2 were related not only to disease activity and autoantibody levels, but also to the imbalance of Th17/Treg immunity in RA patients. Moreover, in individuals with active RA, there was an abnormal increase in NK cell levels, which could be due to high serum IL-2 Levels [18]. The production of IL-2 and the proliferative responses of peripheral blood mononuclear cells in patients with RA and normal controls was investigated. Kitas *et al* study revealed a positive relationship between proliferative responses and IL2-levels with the proportion of CD4+ cells, and an inverse relationship with Tac+ lymphocytes suggested that depressed IL-2 production in RA patients may relate to monocyte effects, but this cannot completely explain the defects observed [19].

IL-2, growth factor for T lymphocytes, exerts its effects through the activation of cell surface receptors called IL-2R. These receptors are found on activated T cells, and the protein can be shed from cell membranes resulting in the detection of a soluble form of IL-2R using enzyme-linked immunosorbent assay. This study analyzed the levels of sIL-2R in the sera of patients with RA over time. The findings indicate that the sIL-2R level in the serum of RA patients reflects the activation of underlying immunopathogenic mechanisms, making it an excellent indicator of clinical disease activity. Moreover, an increasing level of sIL-2 R may predict the exacerbation of disease activity [20].

The genetic risk factors were identified in RA patients. The results showed that a genetic variant (rs791588) in the IL2RA gene was associated with a decreased risk of RA, and two SNPs (rs791588 and rs2281089) were associated with a reduced risk of RA when stratified by gender or age. However, two haplotypes of IL2RA were associated with an increased risk of RA. These findings suggest that inherited genetic alterations at IL2RA may play a role in the development of RA [21]. This study aimed to investigate whether SNPs within the IL2RA/CD25 gene are associated with juvenile idiopathic arthritis (JIA). The IL2RA/CD25 gene is a susceptibility gene for autoimmune diseases due to its role in regulatory T cells. The study found strong evidence that the

IL2RA/CD25 gene is a JIA susceptibility locus, and further investigation is necessary using both genetic and functional approaches [21]. Moreover, IL2RA-rs2104286 and sIL2R α levels have been found to be associated with persistent RA. IL2RA gene variants have been previously shown to have protective effects against multiple sclerosis, diabetes mellitus, and RA. In addition to HLA-SE, IL2RA-rs2104286 is currently the only known genetic variant that is associated with both joint destruction and RA-persistence, highlighting the importance of IL2RA in the development and progression of RA [22].

The study investigated various aspects of the production and function of interleukin-2 (IL-2) using mononuclear cells from synovial fluid (SF), synovial tissue (ST), and peripheral blood (PB) of patients with RA. The findings indicated that both PB and SF rheumatoid lymphocytes produced less IFN-gamma when treated with IL-2 overnight than normal PB lymphocytes. This was inconsistent with the notable improvement in natural killer activity caused by IL-2. Removing adherent cells in synovial fluid did not correct this deficit. These abnormal behaviors of IL-2 and IFN-gamma suggest that impaired T cell function could be a contributing factor in the immunopathogenesis of RA [23]. However, previous studies in patients with RA have produced conflicting findings regarding the relationship between sIL-2R levels and disease activity scores or other laboratory markers of inflammation. A recent study found that low sIL-2R levels might indicate a rapid response to treatment with infliximab in RA patients. However, this marker did not accurately identify patients in remission after 22 wk in their study group. Additionally, Steenbergen *et al* reported that lower sIL-2R levels were associated with sustained remission without the use of disease-modifying antirheumatic drugs in RA patients [4]. The status of regulatory T cells (Tregs) in refractory RA and the potential of low-dose interleukin-2 (IL-2) therapy in restoring the decreased CD4 Tregs was investigated. Results showed that a decrease in peripheral blood CD4 Tregs in patients with refractory RA was associated with continuing disease activation, but not an increase in Th17 cells. Low-dose IL-2 therapy was found to restore decreased CD4 Tregs and promote rapid remission of patients with refractory RA without overtreatment or

observed side effects, making it a potential therapeutic candidate [24]. The potential use of low-dose interleukin-2 (Ld-IL2) as a therapeutic approach to enhance the treatment of RA was investigated through a randomized, double-blind, placebo-controlled trial. The effectiveness and safety of Ld-IL2 in patients with active RA was considered. The findings showed that Ld-IL2 was well-tolerated, and low levels of Treg and high levels of IL-21 were associated with positive responses to Ld-IL2. Therefore, it can be concluded that Ld-IL2 is a safe and effective treatment for RA [25].

Sjögren Syndrome (SS)

Sjögren's syndrome (SS) is a chronic autoimmune disease that is characterized by the loss of function of exocrine glands. The infiltration of exocrine glands by T and B lymphocytes is responsible for the inflammation observed in SS patients. In addition to the loss of exocrine gland function, SS patients may also experience a range of extra-glandular symptoms such as arthralgia, kidney disease, lung disease, and fatigue [26]. SS is characterized by dry mouth (xerostomia), dry eyes (xerophthalmia), and other immune-mediated symptoms. The condition can also cause dryness in the mucosal surfaces of the digestive tract, lungs, and vagina, which is referred to as "Sicca syndrome" or "Sicca Complex." Since it is a systemic illness, SS can impact various organ systems and result in a range of symptoms. These symptoms, which include fatigue, depression, anxiety, and impaired physical performance, can significantly affect a patient's quality of life and daily activities [27].

The etiology of SS, like other autoimmune diseases, is not yet fully understood. However, it is widely recognized that exposure to specific environmental factors may contribute to the dysregulation of the immune system and the onset of the disease in susceptible individuals. The interferon pathway is critical in the early stages of SS by disrupting the innate immune system's barriers [28]. Nonetheless, the adaptive immune system's role is significant in SS development, as persistent B-cell activation and the growth of Th1 and Th17 cells contribute to the disease's progression [29].

Genetic susceptibility plays a significant role in the pathophysiology of SS. Previous studies have identified several genes, including IRF5-TNPO3, STAT4, IL12A,

FAM167A-BLK, DDX6-CXCR5, and TNIP1, may be involved as risk factors for SS. IRF5 and STAT4 have been recognized as susceptibility genes based on genome-wide association analysis [30]. IRF5 activates the expression of several proinflammatory factors downstream of the Toll-like receptor (TLR) and type I interferon (IFN) receptor, while STAT4 plays a role in autoimmune abnormalities through IFN production [31]. Women are more likely than men to develop SS, and studies have identified GTF2I and RBMS3 as the most significant susceptibility genes for pSS in women [32].

Long non-coding RNA (lncRNA) plays a role in gene expression by modifying chromosomes, DNA, transcription, and post-transcriptional modification, as well as the generation of inflammatory mediators, immune cell growth, and differentiation, which contribute to the development of autoimmunity [33]. Dysregulated lncRNAs have been linked to the increased risk of SS [34]. MicroRNAs (miRNAs) also play a role in the development of autoimmune diseases, including SS. pSS patients have decreased expression of miRNA-181a and miRNA-16 in their salivary glands [35], while the levels of miRNA-146a and miRNA-155 in their peripheral blood mononuclear cells are linked to their clinical symptoms. Epigenetic processes, such as DNA methylation and histone modification, may also contribute to the onset of SS [36].

SS is an autoimmune disorder where immune cells and IL-2 signaling are not working correctly. IL-2 is essential for the growth and maintenance of Treg cells. There is potential for the use of low doses of IL-2 to treat autoimmune diseases, but it is uncertain if it can be effective in treating SS or how it works. Research provides evidence that low-dose interleukin-2 is a promising treatment for SS in NOD mice by restoring immunological balance through promoting Treg cells and suppressing germinal center B cells and effector T cells [37]. The effects of low-dose interleukin-2 on exocrine glands in SS were not previously known. This study investigated the impact of low doses of IL-2 on the development and function of salivary glands in a mouse model of SS. Results indicate that low-dose IL-2 treatment improves the exocrine glands' ability to secrete saliva in SS-affected mice, but it does not restore the damaged structure of the glands [38].

25

Primary Sjögren syndrome (pSS) is a systemic autoimmune disease characterized by immune cell dysregulation, and it currently lacks effective treatment options. As a result, investigating potential therapeutic strategies is essential. One such strategy is the use of low-dose interleukin 2 (LD-IL-2), which can be studied for its safety, immunological response, and potential to treat pSS. In a randomized clinical trial, pSS patients responded positively to LD-IL-2 treatment, leading to restored immunological balance through the promotion of regulatory T cells and CD24 high CD27+ B cells [39]. A study was designed to understand the mechanism behind the increased Th17 differentiation in pSS patients and the role of IL-2 in balancing Th17 and Tregs. The findings showed that the increased Th17 generation in pSS was not dependent on Tregs, but rather due to the lack of IL-2-mediated suppression of Th17 differentiation. Therefore, this study revealed a new mechanism of immune suppression mediated by IL-2 in pSS [40].

Systemic Sclerosis (SSc)

21

Systemic sclerosis (SSc) is an autoimmune disease that affects multiple organs, including the skin, joints, tendons, gastrointestinal tract, lungs, heart, blood vessels, and kidneys, due to inflammation and fibrosis. It primarily affects women, with a female to male ratio of 4:1-10:1, depending on age and ethnicity. The disease has two clinical subtypes based on the extent of skin involvement: diffuse cutaneous SSc (dcSSc), which affects the skin proximal to elbows and/or knees, or that affects the thorax and/or abdomen at any given time during the disease, and limited cutaneous SSc (lcSSc), which affects the skin distal to elbows and knees without involvement of the thorax or abdomen [41].

The disease can lead to major disabilities, malnutrition, and decreased quality of life due to vascular complications, cardiopulmonary involvement, inflammatory myopathy, arthritis, and gastrointestinal tract involvement [41]. The immune response cells, inflammatory mediators, fibroblasts, and other components of the extracellular matrix, as well as endothelial damage, play a central role in the disease's numerous pathogenic pathways. This has changed the previous paradigm that the disease was predominantly

fibrotic and is now viewed as a complex syndrome that requires simultaneous treatment of its various pathogenic pathways [41].

The chromosome 4q27 region that contains the IL-2 and IL-21 genes has been linked to various autoimmune diseases, as both genes are involved in immune system functions. This study aimed to investigate the role of the IL-2/IL-21 Locus in SSc. The research found that the allelic combination of rs2069762A-rs6822844T-rs6835457G-rs907715T showed significant association with SSc and the limited cutaneous SSc subtype. Therefore, the study concluded that the IL-2/IL-21 Locus is involved in the genetic susceptibility to SSc. These findings also add to the evidence that the IL-2/IL-21 Locus is a common genetic factor in autoimmune diseases [42].

The connections were investigated between 9 SNPs in the IL10, IL1B, IL1A, IL1RN, IL2, LTA, and IL6 genes and the development of SSc, as well as the clinical subtype of SSc in patients. A total of 78 SSc patients (31 with diffuse SSc and 47 with limited SSc) and 692 healthy blood donors were genotyped for 9 SNPs: IL10 T-3575A, IL10 A-1082G, IL1B C-31T, IL1B C-511T, IL1A C-889T, IL1RN A9589T, IL2 T-384G, LTA T-91G, and IL6 G-174C. The study found that the IL1B and IL2 gene SNPs may contribute to the susceptibility to SSc. Additionally, the IL2-384-G allele may serve as an indicator for the limited phenotype of SSc [43].

IL-2A and IL-12R gene variants have been linked to SSc. IL-2 helps maintain the immune system's balance and tolerance to self, promotes B-cell immunoglobulin production, and stimulates natural killer cell proliferation and differentiation. Two studies explored the role of IL-2 in SSc. The studies found that certain IL-2 receptor alpha gene variants (rs11594656, rs2104286, and rs12722495) were associated with SSc, limited cutaneous SSc, and anticentromere antibody (ACA) positivity. However, the associations were highly dependent on ACA positivity, as removing ACA from the analysis resulted in the loss of association. Among the IL-2 RA gene variants, rs2104286 showed the strongest association with ACA positivity, and the associations with the other variants disappeared after accounting for rs2104286 [44]. The minor allele of rs907715 and rs682284 are linked to SSc. The variant rs682284 specifically affects lcSSc

and ACA positivity. An allelic combination, is rs2069762*A, rs6822844*T-rs6835457G-rs907715* T is linked to both dcSSc and lcSSc. Protective for lcSSc and ACA positive is the T allele for rs6822844 [42].

Basiliximab, a monoclonal antibody, targets the alpha chain (CD25) of the IL-2 receptor and has been suggested as a potential treatment for SSc. This is due to recent findings that suggest a significant role of T effector cells, specifically T-17 and T regulatory subsets, in the pathogenesis of SSc [45]. Schmidt *et al* study suggested that treatment with this medication could improve skin involvement, lung fibrosis, disease progression, and mortality in systemic sclerosis. They based this on the correlation between these factors and serum levels of soluble IL-2 receptor, which could be reduced by the drug [46]. In an accessible SSc research, basiliximab medication was generally well tolerated, and the side effects that were reported were primarily modest [47]. In an open-label study on SSc, minor side-effects were mostly reported, and in general, basiliximab therapy was well tolerated [47].

Relationship between immune system and lung fibrosis in Fra-2-transgenic mice was investigated, which can serve as a model for SSc. The study examined whether an imbalance between effector and regulatory CD4+ T cells may be responsible for the lung phenotype observed in these mice. The results suggest that immunotherapies targeting the restoration of Treg cell homeostasis may be beneficial for SSc. Low-dose IL-2 injection has been suggested as a potential therapy to achieve this, which may be explored further in future studies. SSc is an autoimmune disease with significant pulmonary complications that can decrease life expectancy [48].

23

Multiple Sclerosis (MS)

Multiple sclerosis (MS) is a disease of the nervous system that causes chronic, progressive, and degenerative symptoms. It occurs when the immune system is not functioning properly, leading to damage of the central nervous system, including demyelination and axonal damage. In most cases, the first sign of MS is a demyelinating disease referred to as a clinically isolated syndrome. This involves focal or multifocal areas of the central nervous system, commonly affecting the optic nerve, brainstem, or

spinal cord. It is caused by a disruption in the regulation of the immune system, which may be due to genetic factors and/or environmental triggers such as viral infections. The prevalence of MS is highest among individuals of Caucasian ethnicity and those of northern European descent. The disease is widespread, with approximately 2 million individuals diagnosed worldwide, and the number of cases is projected to increase due to population growth [49]. MS is prevalent in young adults and is the primary cause of non-traumatic disability in this population. MS is more common in females than males, with a ratio of 2-3:1, although there is no gender imbalance in primary progressive MS [49].

28 IL-2 and soluble IL-2 receptor (sIL-2R) levels in serum and CSF could serve as markers of disease activity in MS. A research study involved 63 MS patients, and the results showed that the levels of IL-2 and sIL-2R in the CSF were significantly higher in patients experiencing relapses than those in remission or the control group. Additionally, these levels correlated with disease severity scores, the number of relapses per year, and the total duration of the disease. The findings suggested that there is an association between an activated immune system and MS pathology, and measuring IL-2 and sIL-2R levels could provide a reliable indicator of disease activity in MS patients [50].

The role of CD8⁺ T cells in the development of MS has been established. IL-2R α is crucial for the function of CD8⁺ T cells, and IL2RA gene SNPs increase the risk of MS. In this study, the researchers investigated the methylation and gene expression of the IL2RA gene in isolated CD8⁺ T cells in relation to the MS-associated SNP rs2104286 and soluble IL-2R α (sIL-2R α). The results showed that rs2104286 SNP has a minor effect on CD8⁺ T cells and sIL-2R α might negatively regulate the CD8⁺ T cell response [51].

10 The IL-2/IL-2R pathway is crucial for T cell proliferation, survival, and regulatory T cell production. Genome-wide studies have identified polymorphisms in the IL2/IL21 genes (located in 4q27), as well as in genes encoding the IL2RA and IL2RB subunits (located in 10p15 and 22q13, respectively), that are associated with various autoimmune diseases. In a combined Spanish cohort, regression analyses indicated that two

independent IL2RA association signals, namely rs2104286 and rs11594656/rs35285258, are relevant for MS susceptibility and support their common effect on autoimmune risk. Additionally, the association of IL2/IL21 requires further investigation [52].

The ability to predict the severity of MS in a newly diagnosed patient would allow for more personalized treatment strategies and improved clinical outcomes. Therefore, there is a need for prognostic biomarkers. A study was conducted to evaluate the prognostic value of intrathecal IgM synthesis, as well as cerebrospinal fluid and serum levels of IL-2, IL-6, IL-10, chitinase 3-like 2, and neurofilament heavy chains obtained shortly after the onset of the disease. The study found that the IL-2:IL-6 ratio, IL-2, and chitinase 3-like 2 (all in cerebrospinal fluid) may serve as valuable prognostic biomarkers in the early stages of multiple sclerosis [53].

This research explores the potential therapeutic and protective effects of Tregs, myeloid-derived suppressor cells (MDSCs), and IL-2 on a MS disease model. The study involved immunizing C57BL/6 mice to develop an experimental autoimmune encephalomyelitis (EAE) model, followed by investigating the effects of pre- and post-treatment of Tregs, MDSCs, and IL-2 on inflammation, demyelination in brain tissue, and the number of Treg, granulocytic-MDSC, and Th-17 cells in the spleen. The results showed that pre- and post-treatment with Tregs, MDSCs, and IL-2 prevented EAE induction, with reduced Th-17 cells and suppression of pathological properties, and no weight change in the mice. Therefore, the study concludes that pre- and post-treatment with Tregs, MDSCs, and IL-2 may have the potential to prevent EAE induction [Ghorbani MM].

CONCLUSION

According to the genetic studies of IL-2, gene polymorphism of IL-2 such as IL-2 330/T, IL-2 330/G, rs2069763 are involved in triggering increased risk of SLE. Furthermore, genetic association of IL-2/IL-2R such as rs791588, rs2281089, rs2104286, rs11594656, rs35285258 are significantly associated with RA susceptibility. The IL-2 polymorphism including rs2069762A, rs6822844T, rs6835457G, rs907715T are significant connection with systemic sclerosis. In addition, rs2104286(IL-2), rs11594656 (IL-2RA), rs35285258

(IL-2RB) gene polymorphism are significantly increases the risk of multiple sclerosis. In case of therapeutic approaches, low-dose IL-2 therapy could regulate Tfr and Tfh cells, resulting in a reduction in disease activity in the SLE patients. In addition, elevated sIL-2R levels in the peripheral blood of SLE patients could be linked to an immunoregulatory imbalance, which may contribute to the onset and progression of SLE. Consequently, sIL-2R could potentially be a target for future SLE therapy. Moreover, Ld-IL2 was well-tolerated, and low levels of Treg and high levels of IL-21 were associated with positive responses to Ld-IL2 suggested to be a safe and effective treatment for RA. Additionally, low-dose IL-2 treatment improves the exocrine glands' ability to secrete saliva in SS-affected mice. Whereas, Basiliximab targets the alpha chain of the IL-2 receptor suggested as a potential treatment for SSc. Also, pre- and post-treatment with Tregs, MDSCs, and IL-2 may have the potential to prevent EAE induction in patients with MS. Further studies should be conducted on IL-2 gene polymorphisms in Sjogren syndrome.

20%

SIMILARITY INDEX

PRIMARY SOURCES

1	www.ncbi.nlm.nih.gov Internet	218 words — 3%
2	pubmed.ncbi.nlm.nih.gov Internet	119 words — 2%
3	www.frontiersin.org Internet	110 words — 2%
4	uthealth.influent.utsystem.edu Internet	88 words — 1%
5	onlinelibrary.wiley.com Internet	65 words — 1%
6	www.jrheum.org Internet	55 words — 1%
7	www.alliedmarketresearch.com Internet	54 words — 1%
8	C C Mok. "Pathogenesis of systemic lupus erythematosus", Journal of Clinical Pathology, 7/1/2003 Crossref	52 words — 1%
9	www.njmonline.nl Internet	52 words — 1%

10	www.omicsdi.org Internet	47 words — 1%
11	www.hindawi.com Internet	42 words — 1%
12	www.jci.org Internet	40 words — 1%
13	hdl.handle.net Internet	31 words — < 1%
14	www.mdpi.com Internet	30 words — < 1%
15	www.researchgate.net Internet	30 words — < 1%
16	L A SANTANA-BLANK, M CASTES, M E ROJAS, F VARGAS, D SCOTT-ALGARA. "Evaluation of serum levels of tumour necrosis factor-alpha (TNF-α) and soluble IL-2 receptor (sIL-2R) and CD4, CD8 and natural killer (NK) populations during infrared pulsed laser device (IPLD) treatment", Clinical and Experimental Immunology, 1992 Crossref	24 words — < 1%
17	Dorra Bouzid, Hajer Fourati, Ali Amouri, Isabel Marques, Olfa Abida, Nabil Tahri, Carlos Penha-Gonçalves, Hatem Masmoudi. "Autoimmune diseases association study with the KIAA1109-IL2-IL21 region in a Tunisian population", Molecular Biology Reports, 2014 Crossref	20 words — < 1%
18	Xue Wen, Bin Li. "A population-based study on autoimmune disease", The Lancet, 2023 Crossref	20 words — < 1%

19	rbmb.net Internet	16 words — < 1%
20	res.mdpi.com Internet	16 words — < 1%
21	www.sec.gov Internet	15 words — < 1%
22	Nigel C. Wood, Julian A. Symons, Gordon W. Duff. "Serum interleukin-2-receptor in rheumatoid arthritis: A prognostic indicator of disease activity?", <i>Journal of Autoimmunity</i> , 1988 Crossref	14 words — < 1%
23	garlandsweb.hypermart.net Internet	14 words — < 1%
24	www.medindia.net Internet	14 words — < 1%
25	acrabstracts.org Internet	13 words — < 1%
26	"Abstract Supplement 2018 ACR/ARHP Annual Meeting", <i>Arthritis & Rheumatology</i> , 2018 Crossref	12 words — < 1%
27	Mohammad Mehdi Ghorbani, Touraj Farazmandfar, Saeid Abediankenari, Hadi Hassannia, Zahra Maleki, Majid Shahbazi. "Treatment of EAE mice with Treg, G-MDSC and IL-2: a new insight into cell therapy for multiple sclerosis", <i>Immunotherapy</i> , 2022 Crossref	12 words — < 1%
28	lib.bioinfo.pl Internet	12 words — < 1%

EXCLUDE QUOTES ON

EXCLUDE BIBLIOGRAPHY ON

EXCLUDE SOURCES OFF

EXCLUDE MATCHES < 12 WORDS